{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360021391884114048.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1080/13506129.2023.2232520"}},{"identifier":{"@type":"URI","@value":"https://www.tandfonline.com/doi/pdf/10.1080/13506129.2023.2232520"}},{"identifier":{"@type":"DOI","@value":"10.6084/m9.figshare.23715676.v1"}},{"identifier":{"@type":"DOI","@value":"10.6084/m9.figshare.23715676"}},{"identifier":{"@type":"PMID","@value":"37563759"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study"}],"description":[{"notation":[{"@value":"Longitudinal changes in neurofilament light chain (NfL) levels were evaluated alongside prespecified clinical assessments 24 months into the patisiran Global open-label extension (OLE) study in patients with ATTRv amyloidosis with polyneuropathy. All patients enrolled in the Global OLE, from phase III APOLLO and phase II OLE parent studies, received patisiran. Assessments included measures of polyneuropathy (modified Neuropathy Impairment Score+7 (mNIS+7)), quality of life (QOL; Norfolk QOL-Diabetic Neuropathy questionnaire (Norfolk QOL-DN)), and plasma NfL. Patients receiving patisiran in the parent study (APOLLO-patisiran, <i>n</i> = 137; phase II OLE-patisiran, <i>n</i> = 25) demonstrated sustained improvements in mNIS+7 (mean change from parent study baseline (95% confidence interval): APOLLO-patisiran −4.8 (−8.9, −0.6); phase II OLE-patisiran −5.8 (−10.5, −1.2)) and Norfolk QOL-DN (APOLLO-patisiran −2.4 (−7.2, 2.3)), and maintained reduced NfL levels at Global OLE 24 months. After initiating patisiran in the Global OLE, APOLLO-placebo patients (<i>n</i> = 49) demonstrated stabilized mNIS+7, improved Norfolk QOL-DN, and significantly reduced NfL levels. Patisiran continued to demonstrate an acceptable safety profile. Earlier patisiran initiation was associated with a lower exposure-adjusted mortality rate. Long-term patisiran treatment led to sustained improvements in neuropathy and QOL, with NfL demonstrating potential as a biomarker for disease progression and treatment response in ATTRv amyloidosis with polyneuropathy."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380021391884114056","@type":"Researcher","foaf:name":[{"@value":"Simina Ticau"}],"jpcoar:affiliationName":[{"@value":"Alnylam Pharmaceuticals, Cambridge, MA, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021391884114055","@type":"Researcher","foaf:name":[{"@value":"Emre Aldinc"}],"jpcoar:affiliationName":[{"@value":"Alnylam Pharmaceuticals, Cambridge, MA, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021391884114053","@type":"Researcher","foaf:name":[{"@value":"Michael Polydefkis"}],"jpcoar:affiliationName":[{"@value":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021391884114048","@type":"Researcher","foaf:name":[{"@value":"David Adams"}],"jpcoar:affiliationName":[{"@value":"Neurology Department, AP-HP, CHU Bicêtre, Université Paris-Saclay, Paris-Saclay, France"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021391884114049","@type":"Researcher","foaf:name":[{"@value":"Teresa Coelho"}],"jpcoar:affiliationName":[{"@value":"Centro Hospitalar Universitário Santo António, European Reference Network – EUroNMD, Porto, Portugal"}]},{"@id":"https://cir.nii.ac.jp/crid/1420845751141911168","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"60452885"},{"@type":"NRID","@value":"1000060452885"},{"@type":"CINII_AUTHOR_ID","@value":"DA19472038"},{"@type":"URI","@value":"https://ci.nii.ac.jp/author/DA19472038#entity"},{"@type":"URI","@value":"https://viaf.org/viaf/NII%7CDA19472038"},{"@type":"NRID","@value":"9000018775794"},{"@type":"NRID","@value":"9000020242127"},{"@type":"NRID","@value":"9000414224244"},{"@type":"NRID","@value":"9000411647720"},{"@type":"NRID","@value":"9000404525293"},{"@type":"NRID","@value":"9000409006176"},{"@type":"NRID","@value":"9000404327460"},{"@type":"NRID","@value":"9000411005801"},{"@type":"NRID","@value":"9000345404287"},{"@type":"NRID","@value":"9000404318601"},{"@type":"NRID","@value":"9000399361381"},{"@type":"NRID","@value":"9000237598465"},{"@type":"NRID","@value":"9000415140422"},{"@type":"NRID","@value":"9000410521403"},{"@type":"NRID","@value":"9000379610225"},{"@type":"NRID","@value":"9000405886838"},{"@type":"NRID","@value":"9000403284207"},{"@type":"NRID","@value":"9000021409613"},{"@type":"NRID","@value":"9000021849180"},{"@type":"NRID","@value":"9000413567901"},{"@type":"NRID","@value":"9000399240742"},{"@type":"NRID","@value":"9000410524684"},{"@type":"NRID","@value":"9000241717252"},{"@type":"NRID","@value":"9000412114217"},{"@type":"NRID","@value":"9000326265109"},{"@type":"NRID","@value":"9000019085695"},{"@type":"NRID","@value":"9000408623526"},{"@type":"NRID","@value":"9000411953079"},{"@type":"NRID","@value":"9000345264817"},{"@type":"NRID","@value":"9000356906488"},{"@type":"NRID","@value":"9000018234849"},{"@type":"NRID","@value":"9000391663954"},{"@type":"NRID","@value":"9000004117546"},{"@type":"NRID","@value":"9000411090780"},{"@type":"NRID","@value":"9000398136262"},{"@type":"NRID","@value":"9000405872906"},{"@type":"NRID","@value":"9000408623347"},{"@type":"NRID","@value":"9000408608010"},{"@type":"NRID","@value":"9000391774913"},{"@type":"NRID","@value":"9000359904902"},{"@type":"NRID","@value":"9000409987627"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/3286"}],"foaf:name":[{"@value":"Mitsuharu Ueda"}],"jpcoar:affiliationName":[{"@value":"Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021391884114054","@type":"Researcher","foaf:name":[{"@value":"Cecilia Hale"}],"jpcoar:affiliationName":[{"@value":"Alnylam Pharmaceuticals, Cambridge, MA, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021391884114051","@type":"Researcher","foaf:name":[{"@value":"John Vest"}],"jpcoar:affiliationName":[{"@value":"Alnylam Pharmaceuticals, Cambridge, MA, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021391884114052","@type":"Researcher","foaf:name":[{"@value":"Paul Nioi"}],"jpcoar:affiliationName":[{"@value":"Alnylam Pharmaceuticals, Cambridge, MA, USA"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13506129"},{"@type":"EISSN","@value":"17442818"}],"prism:publicationName":[{"@value":"Amyloid"}],"dc:publisher":[{"@value":"Informa UK Limited"}],"prism:publicationDate":"2023-07-20","prism:volume":"31","prism:number":"1","prism:startingPage":"1","prism:endingPage":"11"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","dc:rights":["http://creativecommons.org/licenses/by/4.0/"],"url":[{"@id":"https://www.tandfonline.com/doi/pdf/10.1080/13506129.2023.2232520"}],"createdAt":"2023-07-20","modifiedAt":"2024-02-25","project":[{"@id":"https://cir.nii.ac.jp/crid/1040299826879600896","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"23K24245"},{"@type":"JGN","@value":"JP23K24245"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23K24245/"}],"notation":[{"@language":"ja","@value":"ATTRアミロイドーシスを真に克服する病態解明とアミロイド・クリアランス療法"},{"@language":"en","@value":"ATTR amyloid clearance for definitive therapy"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004233475904768","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142432797440","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145192742656","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145592308992","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145881239040","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145990738816","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Genotype, echocardiography, and survival in familial transthyretin amyloidosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011146458160768","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011146548040704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011146583623040","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021395484820992","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283692747340160","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Liver Transplantation for Hereditary Transthyretin Amyloidosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360286993334972544","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292621401889408","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298760982739712","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Blood Neurofilament Light Chain: The Neurologist’s Troponin?"}]},{"@id":"https://cir.nii.ac.jp/crid/1360301785306835968","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302871510232832","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Trans-acting Factor May Modify Age at Onset in Familial Amyloid Polyneuropathy ATTRV30M in Portugal"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302871511177088","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Peripheral blood neurofilament light chain levels: the neurologist’s C-reactive protein?"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565170459311616","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Evolving landscape in the management of transthyretin amyloidosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567183772894592","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574093982648576","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Plasma neurofilament light chain concentration in the inherited peripheral neuropathies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094230285824","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574096302625280","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Norfolk <scp>QOL‐DN</scp>: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574096541314560","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Amyloid neuropathies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584346306877056","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846639238486016","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Repurposing Diflunisal for Familial Amyloid Polyneuropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569158885248","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570838809600","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865817592107136","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865818244395776","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993933521664","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993987039104","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994004157824","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Tafamidis delays neurological progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994720673792","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995901651328","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470128937600","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943733898752","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943908530048","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944411444992","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Retrospective study of a TTR FAP cohort to modify NIS + 7 for therapeutic trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945433348608","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945617077632","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418447294336","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Regional difference and similarity of familial amyloidosis with polyneuropathy in France"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418893951488","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS)"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420631122176","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388846350523648","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268932061184","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270903050240","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Amyloid Neuropathies"}]},{"@id":"https://cir.nii.ac.jp/crid/1390585437718774656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"ニューロフィラメント軽鎖は遺伝性ATTRアミロイドーシスの活動性マーカーとして有用か？―文献レビュー"},{"@language":"en","@value":"Is neurofilament light chain useful as a disease progression marker for ATTRv amyloidosis? A literature review"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1080/13506129.2023.2232520"},{"@type":"KAKEN","@value":"PRODUCT-25280437"},{"@type":"OPENAIRE","@value":"doi_dedup___::7fdebc30985cf1024ccaa497508c85b3"},{"@type":"CROSSREF","@value":"10.5692/clinicalneurol.cn-002063_references_DOI_AZ552cqQgYU9un3UO4vBR37YL5J"}]}